Crinetics Pharmaceuticals Appoints Dana Pizzuti, M.D. as Chief Development Officer
October 03, 2022 08:00 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the appointment of Dana Pizzuti, M.D., as chief development officer. Dr. Pizzuti is a...
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 12, 2022 08:00 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on September 10, 2022, the Compensation Committee of Crinetics’ Board of Directors...
Crinetics Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
September 08, 2022 08:00 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX) today announced that company management will present a corporate overview at the H.C. Wainwright 24th Annual...
New Long-Term Safety and Efficacy Data Presented with Paltusotine in Participants Living with Acromegaly
September 06, 2022 08:00 ET
|
Crinetics Pharmaceuticals, Inc.
Open label extension data from investigational compound paltusotine orally presented at the 35th Brazilian Congress of Endocrinology and Metabolism Lowered and maintained IGF-1 at levels comparable...
New Long-Term Safety and Efficacy Data for Investigational Compound Paltusotine to be Presented at the Brazilian Congress of Endocrinology and Metabolism
September 02, 2022 08:00 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX) today announced that Monica R. Gadelha, MD, PhD, professor of endocrinology at the Medical School of the...
Crinetics Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 12, 2022 08:00 ET
|
Crinetics Pharmaceuticals, Inc.
Paltusotine’s Phase 3 PATHFNDR Program in Acromegaly and Phase 2 Program in Carcinoid Syndrome Remain on Track for Top-Line Data in 2023 CRN04894 Phase 1 Data Demonstrated Pharmacologic...
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 10, 2022 16:44 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on August 10, 2022, the Compensation Committee of Crinetics’ Board of Directors...
Additional Analyses of CRN04894 Preclinical and Phase 1 Results to be Presented at the 10th International Congress of Neuroendocrinology
August 04, 2022 08:00 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that Peter J. Trainer, M.D., vice president of clinical endocrinology, will review...
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 12, 2022 17:09 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, July 12, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on July 12, 2022, the Compensation Committee of Crinetics’ Board of Directors granted...
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 10, 2022 16:30 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, June 10, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on June 10, 2022, the Compensation Committee of Crinetics’ Board of Directors granted...